News articles about Endo International PLC (NASDAQ:ENDP) (TSE:ENL) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Endo International PLC earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.8739519274857 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have impacted Accern Sentiment’s scoring:

Endo International PLC (NASDAQ:ENDP) traded up $0.84 during trading on Friday, hitting $6.93. 12,015,572 shares of the stock were exchanged, compared to its average volume of 7,342,887. Endo International PLC has a 12-month low of $5.77 and a 12-month high of $18.63. The company has a debt-to-equity ratio of 10.20, a quick ratio of 0.80 and a current ratio of 1.02. The company has a market cap of $1,360.00, a P/E ratio of 1.23 and a beta of 0.53.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The firm had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. During the same period in the previous year, the firm posted $1.01 EPS. The business’s quarterly revenue was down 11.0% on a year-over-year basis. sell-side analysts forecast that Endo International PLC will post 3.54 earnings per share for the current year.

Several brokerages have recently weighed in on ENDP. Royal Bank Of Canada reiterated a “sector perform” rating and set a $9.00 price target (down previously from $15.00) on shares of Endo International PLC in a research note on Wednesday, August 9th. Morgan Stanley lowered their target price on shares of Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 10th. Deutsche Bank AG set a $13.00 target price on shares of Endo International PLC and gave the company a “buy” rating in a research note on Wednesday, August 9th. Zacks Investment Research cut shares of Endo International PLC from a “hold” rating to a “sell” rating in a research note on Thursday, October 26th. Finally, Citigroup Inc. lowered their target price on shares of Endo International PLC from $9.00 to $7.00 and set a “neutral” rating on the stock in a research note on Friday. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $12.22.

COPYRIGHT VIOLATION NOTICE: “Endo International PLC (ENDP) Receives Coverage Optimism Score of 0.14” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at

In other Endo International PLC news, CEO Paul Campanelli bought 6,500 shares of Endo International PLC stock in a transaction dated Monday, August 14th. The shares were purchased at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the acquisition, the chief executive officer now directly owns 213,620 shares in the company, valued at approximately $1,647,010.20. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders bought 16,000 shares of company stock worth $125,460. Insiders own 0.50% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Insider Buying and Selling by Quarter for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.